BIOCRYST PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $3.72 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2025-02-25
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $3.72M, a 23.25% increase from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $3.02M.
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2022 was -$1.61M.
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2021 was -$1.34M, a 273.51% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2024-12-31 | $3.72M 10-K · filed 2025-02-25 |
| 2023-12-31 | $3.02M 10-K · filed 2025-02-25 |
| 2022-12-31 | -$1.61M 10-K · filed 2025-02-25 |
| 2021-12-31 | -$1.34M 10-K · filed 2024-02-27 |
| 2020-12-31 | $774.00K 10-K · filed 2023-02-27 |
| 2019-12-31 | $691.00K 10-K · filed 2022-02-28 |
| 2018-12-31 | $503.00K 10-K · filed 2021-03-01 |
| 2017-12-31 | $910.00K 10-K · filed 2020-03-13 |
| 2016-12-31 | $1.06M 10-K · filed 2019-03-14 |
| 2015-12-31 | $560.00K 10-K · filed 2018-03-12 |
| 2014-12-31 | $258.00K 10-K · filed 2017-02-27 |
| 2013-12-31 | $738.00K 10-K · filed 2016-02-26 |
| 2012-12-31 | $754.00K 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |